|
Kaftrio
Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators. It is approved for use in the United States for people aged two years and older who have cystic fibrosis with a Cystic fibrosis transmembrane conductance regulator#DeltaF508, F508del mutation or other mutations in the CFTR gene. It is also approved for use in Canada, the European Union, and Australia. Medical uses The combination is indicated for the treatment of people aged two years and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene. Side effects The most common side effects affecting more than 5% of patients are headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increase, nas ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tezacaftor
Tezacaftor is a medication used for the treatment of cystic fibrosis. It is available in fixed-dose combination medications. The combination of tezacaftor with ivacaftor (brand name Symdeko) was approved for medical use in the United States in February 2018, and in Canada in June 2018. As brand name Symkevi it was approved for medical use in the European Union in October 2018. The combination of tezacaftor with elexacaftor and ivacaftor (brand name Trikafta) was approved for medical use in the United States in October 2019, and in Canada in June 2021. As brand name Kaftrio it was approved for medical use in the European Union in August 2020. The combination of tezacaftor with vanzacaftor and deutivacaftor (brand name Alyftrek) was approved for medical use in the United States in December 2024. Mechanism of action Tezacaftor acts as a corrector to help the folding and presentation of the CFTR protein to the cell surface, which improves its function for individuals with a ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
